FindTrial
Sign In

HRS-4642

DRUG9 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, Zhejiang University, West China Hospital, Shanghai Zhongshan Hospital

Conditions

Advanced KRAS G12D Mutant Solid TumorsAdvanced Solid TumorsDrug InteractionsLocally Advanced Colorectal CancerMetastatic Pancreatic CarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Active, not recruitingNCT05533463
Jiangsu HengRui Medicine Co., Ltd.Advanced KRAS G12D Mutant Solid Tumors
Start: 2022-09-21End: 2025-12-30Updated: 2025-09-08
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Active, not recruitingNCT06385678
Jiangsu HengRui Medicine Co., Ltd.Advanced KRAS G12D Mutant Solid Tumors
Start: 2024-07-05End: 2026-08-31Updated: 2025-09-19
Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma
RecruitingNCT06427239
Fudan UniversityPancreatic Cancer
Start: 2024-06-17End: 2028-03-01Target: 130Updated: 2026-05-26
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
RecruitingNCT06520488
Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors
Start: 2024-08-09End: 2027-07-31Target: 118Updated: 2025-09-22
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
Active, not recruitingNCT06773130
West China HospitalPancreatic Ductal Adenocarcinoma (PDAC)
Start: 2025-02-10End: 2027-03-01Target: 20Updated: 2026-05-28
Effect of Itraconazole on the Pharmacokinetics of Intravenous HRS-4642 in Healthy Participants
Not yet recruitingNCT07894679
The Third Xiangya Hospital of Central South UniversityDrug Interactions
Start: 2026-10-01End: 2026-11-01Target: 18Updated: 2026-10-26

Phase 2

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
RecruitingNCT06770452
Zhejiang UniversityMetastatic Pancreatic Carcinoma
Start: 2025-03-25End: 2028-02-01Target: 133Updated: 2026-06-03
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
RecruitingNCT06938282
Shanghai Zhongshan HospitalPancreatic Cancer
Start: 2025-06-23End: 2029-04-30Target: 60Updated: 2026-08-26
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Not yet recruitingNCT07503639
Fudan UniversityLocally Advanced Colorectal Cancer
Start: 2026-04-01End: 2030-04-01Target: 134Updated: 2026-03-31

Related Papers

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.
2026-09-16
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS<sup>G12D</sup>-mutant pancreatic cancer: a phase 1b/2 trial.
2026-07-09
HRS-4642 combined with adebrelimab in previously treated patients with metastatic pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology2026-05-27
HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial
Frontiers in Pharmacology2025-07-04